Effect of granulocyte colony stimulating factor treatment on ex vivo cytokine production by blood cells of patients after chemotherapy or radiotherapy.
We explored ex vivo alterations in the cytokine release of stimulated blood cells taken from 8 patients with hematological malignancies who, after chemotherapy or radiotherapy developed leukopenia, and were treated for 3-7 days subcutaneously with granulocyte colony stimulating factor (G-CSF), daily, dose of 5 microg/kg of body weight. Blood was also taken from 8 healthy controls not treated with G-CSF and from patients before and 24 h after last dose of G-CSF and ex vivo treated with interferon (IFN) inducers: Newcastle disease virus (NDV), phytohemagglutinin (PHA), concanavalin A (Con A) and with tumor necrosis factor (TNF) inducer--lipopolysaccharide (LPS). Blood cells of patients before G-CSF treatment exhibited ex vivo a low ability to produce IFN-gamma in comparison to controls. After G-CSF therapy a significant increase in IFN-alpha production ability was detected. We conclude that G-CSF treatment for 3-7 days does not only increase the number of white blood cells (WBC) and neutrophilic granulocytes but also modify the host response of patients with hematological malignancies to microbial infections.
Kamińska
T
T
Department of Virology and Immunology, Maria Curie-Skłodowska University, Lublin, Poland.
Dmoszyńska
A
A
Hus
I
I
Croneck
A W
AW
Kandefer-Szerszeń
M
M
D000293:Adolescent; D000328:Adult; D016207:Cytokines / Q000096:biosynthesis*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006098:Granulocytes / Q000187:drug effects* / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy* / Q000276:immunology; D011994:Recombinant Proteins
D016207:Cytokines; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor